In contrast, there was a greater effect of major toxic effects when they resulted in a lower efficacy of HAART. Without the clinical benefits associated with HAART, patients experienced HIV disease progression before the development HCV-related end-stage liver disease; thus, they received minimal life-extending benefit from HCV treatment despite accruing its treatment costs.